Optiject (Ioversol)

Ioversol, the active ingredient in Optiject, is a non‑ionic low‑osmolality contrast medium presented as a sterile aqueous solution for intravascular injection use. It enhances the visibility of vascular structures and organs during diagnostic imaging procedures in adult and paediatric patients. GNH USA supplies Optiject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Optiject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Optiject is a low‑osmolality iodine‑based contrast agent used in radiographic examinations that require enhanced vascular and organ delineation.

- X‑ray angiography: improves visualization of blood vessels and helps detect stenoses or occlusions. - Computed tomography (CT) scanning: provides high‑contrast images of abdominal, thoracic and cerebral structures. - Intravenous urography: enhances delineation of the urinary collecting system for diagnostic assessment. - Myelography: facilitates clear imaging of the spinal canal and nerve roots. - Endovascular interventions: aids in real‑time guidance of catheter‑based procedures.

Adverse reactions to Optiject may vary in frequency and severity.

Common Side Effects: - Warm sensation or flushing: mild, transient feeling of heat. - Nausea or vomiting: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Metallic taste: brief alteration of taste perception. - Injection site discomfort: mild pain or irritation at the site of administration.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of airway swelling, hypotension, or urticaria. - Contrast‑induced nephropathy: acute decline in renal function, particularly in at‑risk patients. - Cardiovascular collapse: sudden drop in blood pressure or arrhythmia. - Pulmonary edema: fluid accumulation in the lungs causing breathing difficulty. - Seizures: rare neurologic events linked to severe hypersensitivity.

When using Optiject, clinicians should assess patient history and monitor for reactions throughout the procedure.

- Renal impairment: evaluate kidney function and consider alternative agents if severe. - History of iodine allergy: perform allergy testing or choose a non‑iodinated contrast medium. - Thyroid disorders: monitor thyroid function in patients with hyperthyroidism. - Cardiovascular disease: observe hemodynamic status during injection. - Pregnancy and lactation: use only if the diagnostic benefit outweighs potential fetal risk. - Store at below 25°C: keep in the original container, protect from light and moisture.

Optiject may interact with other medications or substances that affect renal function or hypersensitivity risk.

Major Interactions (Avoid): - Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B): combined use can worsen kidney injury. - Metformin: risk of lactic acidosis if renal function declines after contrast exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia that signals an allergic reaction. - ACE inhibitors/ARBs: can potentiate contrast‑induced nephropathy; monitor creatinine. - Diuretics: may affect fluid balance and renal clearance of the contrast. - NSAIDs: increase risk of renal impairment when used with contrast media.